NASDAQFinancialsBanks - RegionalSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HFBL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Net income grows to at least $1.47M by 2026-Q3 | Net income rose from $732K to $1.47M in two years. | Intact | net income falls below $732K in any quarter through 2026-Q3 | Net income: $1.428M FY2026-Q4; GAAP. Published target: >= $1.47M net income. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 25, 20261,428,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
HFBL is a small financial business with a recent record of stronger earnings, so its thesis rests on continued execution rather than a turnaround. The thesis is intact this week, but high risk and neutral management signals call for attention to the quality and consistency of growth.
Valuation is described as cheap versus peers, and the priced-in tag says expectations are justified, with low fragility. The valuation score fell from 82 to 62, but the evidence does not explain what market expectations specifically assume.
Near term, earnings momentum has been strong: September-quarter net income rose from $1.599 million to $1.911 million, and fiscal-year net income rose from $3.888 million to $6.174 million. Loan balances increased in the latest quarter, but deposits slipped, while higher credit-loss provisions and non-interest costs are offsets; maintaining profitability and growing both loans and deposits remain management priorities.
The multi-year thesis depends on continued earnings growth and loan expansion without a lasting rise in credit costs or further deposit weakness. Near term, a guidance cut or rate cuts from the current 3.88% are identified as risks, while continued strong results and higher guidance from sector peers could support financial-sector momentum.
Over the next 1 to 3 years, HFBL’s earnings progress supports an intact long-term thesis, but high risk and uneven deposit growth leave execution and the rate backdrop as important swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated across all 3 supplied transcript quarters. Net income for the September quarter was $1.911 million versus $1.599 million a year earlier, and fiscal-year net income was $6.174 million versus $3.888 million. The financial trajectory is delivering, although the latest quarter’s higher provision for credit losses and non-interest expense are relevant offsets.
Diluted EPS rises to at least $0.48 by 2026-Q3 | A primary condition in Home Federal Bancorp Inc of Louisiana's published investment case. The stated target is >= $0.48 diluted EPS. | Improving | diluted EPS falls below $0.24 in any quarter through 2026-Q3 | Diluted EPS: $0.47 per share FY2026-Q4; GAAP. Published target: >= $0.48 diluted EPS. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 25, 20260.47 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated across all 3 supplied transcript quarters. Net income for the September quarter was $1.911 million versus $1.599 million a year earlier, and fiscal-year net income was $6.174 million versus $3.888 million. The financial trajectory is delivering, although the latest quarter’s higher provision for credit losses and non-interest expense are relevant offsets. Delivery assessment Oct 31, 2026 |
Stock price remains near or below $23 fair value | The stock trades cheap with a price near $23 and a low risk profile. | Under Pressure | price rises more than 10% above $23 fair value without earnings growth | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.